AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7520257 — intervention group
Group type: COMPARATOR
Intervention: Controlled ventilation to an initial PETCO2 of 4 kPa (30 mmHg) (Group 3)
Number of subjects: 40
Study 7520257 — intervention group
Group type: COMPARATOR
Intervention: Controlled ventilation to an initial PETCO2 of 5 kPa (37 mmHg) (Group 4)
Number of subjects: 40
Study 2731311 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 g magnesium sulfate infused over 4.5 h
Number of subjects: 20
Study 2731311 — intervention group
Group type: COMPARATOR
Intervention: Isotonic sodium chloride infused over 4.5 h
Number of subjects: 20
Study 2731311 — intervention group
Group type: COMPARATOR
Intervention: Standard antiemetic regimen (10 mg diazepam and 0.5 mg/kg metoclopramide every 2 h)
Number of subjects: 20
Study 30260776 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 days of sequential therapy (pantoprazole 40 mg bid, amoxicillin 1 g bid for 5 d, followed by pantoprazole 40 mg bid, clarithromycin 500 mg bid, and metronidazole 500 mg bid for additional 5 d)
Number of subjects: 206
Study 30260776 — intervention group
Group type: COMPARATOR
Intervention: 10 days of triple therapy (pantoprazole 40 mg bid, amoxicillin 1 g bid, and clarithromycin 500 mg bid)
Number of subjects: 206
Study 30260776 — intervention group
Group type: COMPARATOR
Intervention: 14 days of triple therapy (pantoprazole 40 mg bid, amoxicillin 1 g bid, and clarithromycin 500 mg bid)
Number of subjects: 206
Study 27631874 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention + activity monitoring (INT+)
Number of subjects: 35
Study 27631874 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (INT)
Number of subjects: 35
Study 27631874 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 35
Study 26202898 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic adipose-derived mesenchymal stem cells (allo-ASC) injected with fibrin glue
Number of subjects: 12
Study 23953873 — intervention group
Group type: EXPERIMENTAL
Intervention: Hiking (2-3 hikes/week, 2-2.5 hours each for 9 weeks)
Number of subjects: 20
Study 23953873 — intervention group
Group type: COMPARATOR
Intervention: Control period (9 weeks without hiking)
Number of subjects: 20
Study 21785373 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month hormone therapy suspension
Number of subjects: 1405
Study 21785373 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-month hormone therapy suspension
Number of subjects: 1405
Study 21785373 — intervention group
Group type: COMPARATOR
Intervention: Control group (continued hormone therapy)
Number of subjects: 1405
Study 18198394 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 1471
Study 18198394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1471
Study 15721471 — intervention group
Group type: EXPERIMENTAL
Intervention: Head cooling for 72 h, within 6 h of birth, with rectal temperature maintained at 34‐35 degrees C (n=116)
Number of subjects: 234
Study 15721471 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (n=118)
Number of subjects: 234
Study 12869909 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (10 days therapy)
Number of subjects: 45
Study 12869909 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin (10 days therapy)
Number of subjects: 45
Study 12869909 — intervention group
Group type: COMPARATOR
Intervention: Control (no therapy)
Number of subjects: 45
Study 12869909 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 45
Study 10560998 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliopancreatic diversion
Number of subjects: 16
Study 10560998 — intervention group
Group type: COMPARATOR
Intervention: Naloxone infusion
Number of subjects: 16
Study 8826687 — intervention group
Group type: EXPERIMENTAL
Intervention: Life events reported before onset of panic disorder/agoraphobia
Number of subjects: 187
Study 2050231 — intervention group
Group type: EXPERIMENTAL
Intervention: Dithranol
Number of subjects: 0
Study 2050231 — intervention group
Group type: EXPERIMENTAL
Intervention: Etretinate
Number of subjects: 0
Study 2050231 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 13‐cis‐retinoic acid
Number of subjects: 0
Study 2050231 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinoids
Number of subjects: 0
Study 6403342 — intervention group
Group type: EXPERIMENTAL
Intervention: Progabide
Number of subjects: 20
Study 30892000 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 30892000 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 28544581 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH XR‐ODT (2 × 30 mg)
Number of subjects: 42
Study 28544581 — intervention group
Group type: COMPARATOR
Intervention: Reference medication (60 mg)
Number of subjects: 42
Study 28544581 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH XR‐ODT and Reference medication
Number of subjects: 42
Study 26564793 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal health and well-being checklist used by intervention group nurses
Number of subjects: 123
Study 26564793 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained domestic violence screening practices
Number of subjects: 123
Study 26564793 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalization of domestic violence screening
Number of subjects: 123
Study 25243994 — intervention group
Group type: EXPERIMENTAL
Intervention: Low supervisor-focused interpersonal justice climate
Number of subjects: 0
Study 25243994 — intervention group
Group type: COMPARATOR
Intervention: High supervisor-focused interpersonal justice climate
Number of subjects: 0
Study 22840447 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg albendazole
Number of subjects: 229
Study 22840447 — intervention group
Group type: COMPARATOR
Intervention: 500 mg mebendazole
Number of subjects: 229
Study 22840447 — intervention group
Group type: EXPERIMENTAL
Intervention: albendazole
Number of subjects: 229
Study 22840447 — intervention group
Group type: COMPARATOR
Intervention: mebendazole
Number of subjects: 229
Study 19826895 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliohypogastric neurectomy and subcutaneous transposition of the spermatic cord
Number of subjects: 54
Study 19826895 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein hernia repair with neurectomy and new procedure
Number of subjects: 54
Study 19826895 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein operation only
Number of subjects: 54
Study 18021879 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers of > or =15 cigarettes per day
Number of subjects: 28236
Study 18021879 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers of > or =25 cigarettes per day
Number of subjects: 28236
Study 18021879 — intervention group
Group type: COMPARATOR
Intervention: Former smokers
Number of subjects: 28236
Study 18021879 — intervention group
Group type: COMPARATOR
Intervention: Never smokers
Number of subjects: 28236
Study 18021879 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers of 1 to 14 cigarettes per day
Number of subjects: 28236
Study 17493059 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral trial
Number of subjects: 65
Study 12802820 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser photocoagulation
Number of subjects: 0
Study 12802820 — intervention group
Group type: EXPERIMENTAL
Intervention: Random effects approach
Number of subjects: 0
Study 12802820 — intervention group
Group type: EXPERIMENTAL
Intervention: Grouped proportional hazards regression model
Number of subjects: 0
Study 12802820 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic logistic regression model
Number of subjects: 0
Study 11145488 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine (6-12 mg daily)
Number of subjects: 120
Study 11145488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 9163263 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine 650 mg
Number of subjects: 59
Study 9163263 — intervention group
Group type: COMPARATOR
Intervention: Prilocaine 500 mg
Number of subjects: 59
Study 1607520 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated 90-min regimen of rt-PA (100 mg total: 15 mg bolus, 50 mg over 30 min, 35 mg over 60 min)
Number of subjects: 281
Study 1607520 — intervention group
Group type: COMPARATOR
Intervention: Standard 3-h regimen of rt-PA (100 mg total: 10 mg bolus, 50 mg for the 1st h, 20 mg/h for 2 h)
Number of subjects: 281
Study 1607520 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated 90-min regimen of rt-PA (100 mg total)
Number of subjects: 281
Study 1607520 — intervention group
Group type: COMPARATOR
Intervention: Standard 3-h regimen of rt-PA (100 mg total)
Number of subjects: 281
Study 1607520 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Accelerated and Standard)
Number of subjects: 281
Study 2933951 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 215
Study 31594738 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention to promote CC screening
Number of subjects: 355
Study 31594738 — intervention group
Group type: COMPARATOR
Intervention: Referral only (control condition)
Number of subjects: 355
Study 29987321 — intervention group
Group type: EXPERIMENTAL
Intervention: Early introduction group (EIG) - infants continued to breastfeed while introducing nonallergenic and then 6 allergenic foods
Number of subjects: 1303
Study 29987321 — intervention group
Group type: COMPARATOR
Intervention: Standard introduction group (SIG) - followed British infant feeding guidelines (exclusive breastfeeding to around age 6 months)
Number of subjects: 1303
Study 26588006 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic medication dispenser (EMD) used for 1 year
Number of subjects: 80
Study 26588006 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EMD)
Number of subjects: 80
Study 26588006 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic medication dispenser (EMD)
Number of subjects: 80
Study 24616136 — intervention group
Group type: EXPERIMENTAL
Intervention: Training family physicians to deliver a brief intervention during consultations
Number of subjects: 594
Study 24616136 — intervention group
Group type: COMPARATOR
Intervention: Usual care only (Control)
Number of subjects: 594
Study 24616136 — intervention group
Group type: EXPERIMENTAL
Intervention: Training family physicians to deliver a brief intervention (restricted analysis to patients with excessive substance use at baseline)
Number of subjects: 594
Study 24616136 — intervention group
Group type: COMPARATOR
Intervention: Usual care only (Control, restricted analysis to patients with excessive substance use at baseline)
Number of subjects: 594
Study 22059531 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulimia nervosa (BN)
Number of subjects: 135
Study 22059531 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating disorder not otherwise specified-bulimia type (EDNOS-BN)
Number of subjects: 135
Study 22059531 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 135
Study 19690954 — intervention group
Group type: EXPERIMENTAL
Intervention: H + D (trastuzumab plus docetaxel)
Number of subjects: 107
Study 19690954 — intervention group
Group type: COMPARATOR
Intervention: H ‐‐> H + D (trastuzumab monotherapy followed by trastuzumab plus docetaxel)
Number of subjects: 107
Study 18555937 — intervention group
Group type: EXPERIMENTAL
Intervention: G-ER BID (600 mg at 8 am and 1200 mg at 8 pm)
Number of subjects: 21
Study 18555937 — intervention group
Group type: EXPERIMENTAL
Intervention: G-ER QD (1800 mg at 8 pm)
Number of subjects: 21
Study 18555937 — intervention group
Group type: COMPARATOR
Intervention: G-IR TID (600 mg at 8 am, 2 pm, and 8 pm)
Number of subjects: 21
Study 16307945 — intervention group
Group type: EXPERIMENTAL
Intervention: Excisional biopsy
Number of subjects: 2182
Study 16307945 — intervention group
Group type: EXPERIMENTAL
Intervention: Incisional biopsy
Number of subjects: 2182
Study 16307945 — intervention group
Group type: EXPERIMENTAL
Intervention: Shave biopsy
Number of subjects: 2182
Study 16307945 — intervention group
Group type: COMPARATOR
Intervention: All biopsy types
Number of subjects: 2182
Study 11907659 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant inflation flow (CF) at 0.40 l/s
Number of subjects: 10
Study 11907659 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant inflation flow (CF) at 0.70 l/s
Number of subjects: 10
Study 11907659 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant inflation flow (CF) at 1.10 l/s
Number of subjects: 10
Study 11907659 — intervention group
Group type: EXPERIMENTAL
Intervention: Decelerating inflation flow (DF) at 0.40 l/s
Number of subjects: 10
Study 11907659 — intervention group
Group type: EXPERIMENTAL
Intervention: Decelerating inflation flow (DF) at 0.70 l/s
Number of subjects: 10
Study 11907659 — intervention group
Group type: EXPERIMENTAL
Intervention: Decelerating inflation flow (DF) at 1.10 l/s
Number of subjects: 10
Study 11907659 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant inflation flow (CF)
Number of subjects: 10
Study 11907659 — intervention group
Group type: EXPERIMENTAL
Intervention: Decelerating inflation flow (DF)
Number of subjects: 10
Study 10396167 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 21
Study 10396167 — intervention group
Group type: COMPARATOR
Intervention: Supportive counselling/psychoeducation (SC)
Number of subjects: 21
Study 9082759 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 110
Study 9082759 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid
Number of subjects: 110
Study 9082759 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 110
Study 9082759 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 110
Study 9082759 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotic treatment)
Number of subjects: 110
Study 1680247 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphasalazine
Number of subjects: 9
Study 1680247 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine
Number of subjects: 9
Study 1680247 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro preincubation with sulphasalazine and mesalazine
Number of subjects: 9
Study 1680247 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 9
Study 6849209 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole + Gentamicin (M + G)
Number of subjects: 141
Study 6849209 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin + Gentamicin (C + G)
Number of subjects: 141
Study 6849209 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (M)
Number of subjects: 141
Study 6849209 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin (C)
Number of subjects: 141
Study 30818068 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymus preservation (TP)
Number of subjects: 54
Study 30818068 — intervention group
Group type: COMPARATOR
Intervention: Bilateral thymectomy (BT)
Number of subjects: 54
Study 29980333 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg/0.05 ml)
Number of subjects: 328
Study 29980333 — intervention group
Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation (PRP)
Number of subjects: 328
Study 27814737 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg daily for 3 months)
Number of subjects: 80
Study 27814737 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose monohydrate, daily for 3 months)
Number of subjects: 80
Study 24443804 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular hyaluronic acid (IA-HA) injection once a week for five weeks
Number of subjects: 200
Study 24443804 — intervention group
Group type: COMPARATOR
Intervention: Oral non-steroidal anti-inflammatory drugs (NSAIDs) three times per day for five weeks
Number of subjects: 200
Study 24443804 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular hyaluronic acid (IA-HA) injection
Number of subjects: 200
Study 22448872 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise + vitamin D (800 IU/d)
Number of subjects: 409
Study 22448872 — intervention group
Group type: COMPARATOR
Intervention: exercise + placebo
Number of subjects: 409
Study 22448872 — intervention group
Group type: EXPERIMENTAL
Intervention: no exercise + vitamin D (800 IU/d)
Number of subjects: 409
Study 22448872 — intervention group
Group type: COMPARATOR
Intervention: no exercise + placebo
Number of subjects: 409
Study 19282413 — intervention group
Group type: EXPERIMENTAL
Intervention: Night splinting
Number of subjects: 70
Study 19282413 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve gliding
Number of subjects: 70
Study 19282413 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 70
Study 17190624 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance measures
Number of subjects: 121
Study 17190624 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact allergens (positive test)
Number of subjects: 121
Study 16038476 — intervention group
Group type: EXPERIMENTAL
Intervention: tenofovir+didanosine+efavirenz (arm C)
Number of subjects: 28
Study 16038476 — intervention group
Group type: EXPERIMENTAL
Intervention: tenofovir+lamivudine+efavirenz (arm B)
Number of subjects: 28
Study 16038476 — intervention group
Group type: EXPERIMENTAL
Intervention: zidovudine+lamivudine+lopinavir/ritonavir (arm A)
Number of subjects: 28
Study 11929758 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor V Leiden
Number of subjects: 1023
Study 11929758 — intervention group
Group type: EXPERIMENTAL
Intervention: APC resistance
Number of subjects: 1023
Study 11929758 — intervention group
Group type: EXPERIMENTAL
Intervention: HR2 haplotype homozygosity
Number of subjects: 1023
Study 11929758 — intervention group
Group type: EXPERIMENTAL
Intervention: HR2 haplotype (carriers)
Number of subjects: 1023
Study 11929758 — intervention group
Group type: EXPERIMENTAL
Intervention: Double heterozygotes for HR2 and factor V Leiden
Number of subjects: 1023
Study 11929758 — intervention group
Group type: EXPERIMENTAL
Intervention: High factor V antigen plus factor V Leiden
Number of subjects: 1023
Study 11929758 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor V antigen
Number of subjects: 1023
Study 9464212 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK‐4 (N = 15)
Number of subjects: 30
Study 9464212 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 15)
Number of subjects: 30
Study 7659436 — intervention group
Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory (BDI)
Number of subjects: 247
Study 7659436 — intervention group
Group type: EXPERIMENTAL
Intervention: External psychological measures and selected questionnaire items
Number of subjects: 247
Study 2766083 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye movement perimetry with Octopus perimeter
Number of subjects: 23
Study 795608 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily tablet preparation containing 1.5 mg fluphenazine plus 30 mg nortriptyline taken at night
Number of subjects: 223
Study 795608 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily tablet preparation containing 1.5 mg fluphenazine plus 30 mg nortriptyline taken in the morning
Number of subjects: 223
Study 795608 — intervention group
Group type: EXPERIMENTAL
Intervention: Three drug schemes including 1 tablet t.d.s. (three times daily)
Number of subjects: 223
Study 31295907 — intervention group
Group type: EXPERIMENTAL
Intervention: MyMAFI mobile application
Number of subjects: 36
Study 31295907 — intervention group
Group type: COMPARATOR
Intervention: Standard paper-based format
Number of subjects: 36
Study 28938966 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 1415
Study 28938966 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 1415
Study 25372450 — intervention group
Group type: EXPERIMENTAL
Intervention: Purse-string suture
Number of subjects: 44
Study 25372450 — intervention group
Group type: COMPARATOR
Intervention: Second intention healing
Number of subjects: 44
Study 24280466 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Western medicine plus Bu‐Fei Jian‐Pi granules, Bu‐Fei Yi‐Shen granules, and Yi‐Qi Zi‐Shen granules
Number of subjects: 352
Study 24280466 — intervention group
Group type: COMPARATOR
Intervention: Conventional Western medicine
Number of subjects: 352
Study 21685187 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs near the HLA region on chromosome 6p21 and in an intergenic region on chromosome 2q21
Number of subjects: 3441
Study 21685187 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidate SNPs within cholinergic receptors, nicotinic, alpha 3/5 (CHRNA3/CHRNA5)
Number of subjects: 3441
Study 21685187 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidate SNP CYP2A6
Number of subjects: 3441
Study 21685187 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidate SNP rs3025343 in DBH
Number of subjects: 3441
Study 19297141 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 800mcg twice daily (starting with 800mcg hourly for 3h after randomization)
Number of subjects: 130
Study 19297141 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone 40mg once daily for 2 weeks
Number of subjects: 130
Study 19297141 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide
Number of subjects: 130
Study 19297141 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 130
Study 16806614 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal voluntary contractions (Strength)
Number of subjects: 31
Study 16806614 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue test to exhaustion
Number of subjects: 31
Study 16806614 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic indices of fatigue
Number of subjects: 31
Study 16806614 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic indices of neuromuscular activation patterns
Number of subjects: 31
Study 14872449 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine
Number of subjects: 5
Study 14872449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 16094787 — intervention group
Group type: EXPERIMENTAL
Intervention: Concept mapping
Number of subjects: 0
Study 16094787 — intervention group
Group type: COMPARATOR
Intervention: Control group (no concept mapping)
Number of subjects: 0
Study 10487800 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (33 mg/day)
Number of subjects: 199